The present invention relates to genetically modified CD34+ hematopoietic cells which overexpress a BCL-xL protein, cell populations comprising such cells and their medical uses. The present invention also relates to methods of enforced BCL-xL expression in hematopoietic cells. Such enforced expression results in an increase in hematopoietic cell viability, expansion, and engraftment ability.
展开▼